Drug intelligence / Profile preview

sidazumab

Development stage: Unknown
Lead developer: 山东泰泽惠康生物医药
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Sidazumab (ZW106-2) is a humanized monoclonal antibody agonist targeting 4-1BB (CD137), a co-stimulatory member of the tumor necrosis factor receptor (TNFR) superfamily. Developed by Shandong Taize Huikang Biopharmaceutical, sidazumab is designed to enhance anti-tumor immunity by binding to 4-1BB expressed on activated T cells and natural killer (NK) cells, thereby promoting their proliferation, survival, and effector functions. The drug is currently in Phase 1 clinical development in China for the treatment of advanced solid tumors, including melanoma and urothelial carcinoma, particularly in patients who have progressed on or are intolerant to standard therapies.

Other names: sidazumab

Targets

TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on sidazumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sidazumab.

Explore the full profile